RE:RE:no insider buying at allFriesen did the buying prior to stock options being granted...@ $0.30 per share. Fortunate they have not purchased via stock options; could hurt the valuation. 9 years till the patent expires on Aggrastat...hopefully Medicure can get the transdermal Aggrastat approved by then and we are off to the races again.